Graph AI, developer of the AI-native pharmacovigilance platform Graph Safety, announced a $13.3 million Series A funding round on Thursday. According to reports from Business Standard, the funding round was led by Insight Partners, with participation from existing investor Bessemer Venture Partners. The company plans to use this funding to accelerate its expansion across the United States and Europe, with the latest reports confirming that Bessemer Venture Partners has increased its stake in the company.
Graph Safety combines AI with deterministic controls, validation layers and end-to-end audit trails designed for regulated pharmacovigilance environments. As reported by Business Standard, the platform has been designed with reference to applicable regulatory requirements and evolving expectations for AI in medicines development and patient safety. In live deployments, the platform has demonstrated significant improvements, reducing case processing turnaround time from more than three hours to under 10 minutes, representing a reduction of more than 90 percent, and lowering operating costs by up to 66 percent.
Since raising its seed round in October 2025, Graph AI has brought two modules to market: Intake, which captures and triages incoming adverse-event reports across every channel, and Nucleus, an intelligent safety database that automates case processing end to end. According to Business Standard, a third module called Report for automated aggregate reporting is launching this month. The company has onboarded pharmaceutical and biotech customers across North America and other markets, and secured design partnerships for upcoming modules, including Signal, which surfaces emerging safety signals and patterns across cases.
Raghav Parvataraju, CEO of Graph AI, emphasized the company's approach to pharmacovigilance transformation, stating that the technology is not replacing human judgment but rather building technology that allows experts to apply it where it matters most. As reported by Business Standard, he clarified that the technology reallocates safety experts' time from operational tasks to higher-value analysis and decision-making, with accountability and oversight preserved through traceable outputs. The platform aligns with evolving regulatory frameworks including the FDA's risk-based credibility assessment for AI in regulatory decision-making, the EU Artificial Intelligence Act, and CIOMS guidance on AI in pharmacovigilance.
